文献速递中枢神经肿瘤放疗放疗物理与技术

五分割立体定向放疗脑转移瘤症状性放射性坏死的剂量学预测因素

Dosimetric predictors of symptomatic radiation necrosis after five-fraction radiosurgery for brain metastases.
PubMed 文献 · Radiother Oncol · 2020-12-11

多中心回顾性分析83例患者117个脑转移灶接受五分割立体定向放疗(5fSRS),中位剂量30 Gy,中位随访10.3个月,症状性放射性坏死(sRN)累积发生率15%;既往SRS史和未受累脑组织V25/V30体积是sRN的显著预测因素。

要点

  • 5fSRS后sRN累积发生率15%,中位出现时间6.9个月。
  • 既往接受过SRS的病灶sRN风险显著升高(HR 7.48)。
  • 无既往SRS者,BrainV25>16 cm3或BrainV30>10 cm3与sRN风险显著相关。

核心结论

  • BrainV25和BrainV30是5fSRS治疗脑转移瘤后sRN的显著剂量学预测因素。
  • 无既往SRS时,保持BrainV25<16 cm3且BrainV30<10 cm3可能降低sRN风险。

研究设计与样本

  • 多机构回顾性研究,纳入83例患者的117个脑转移灶,均接受5fSRS。
  • 采用Gray竞争风险和Cox回归分析sRN累积发生率及预测因素。

主要发现

  • 5fSRS中位剂量30 Gy(范围25-40),21个病灶(18%)有既往SRS史。
  • 中位随访10.3个月(范围3-52),sRN累积发生率15%,中位至sRN时间6.9个月(范围1.8-31.7)。
  • 既往SRS病灶sRN风险显著更高(HR 7.48,95%CI 2.57-21.8)。
  • 无既往SRS病灶中,BrainV25(HR 1.07,95%CI 1.02-1.12)和BrainV30(HR 1.07,95%CI 1.01-1.33)与sRN显著相关。
  • 无既往SRS病灶中,BrainV25>16 cm3(HR 11.7,95%CI 1.47-93.3)和BrainV30>10 cm3(HR 7.08,95%CI 1.52-33.0)与sRN风险显著升高相关。

关键数值与推荐

  • 无既往SRS病灶:BrainV25>16 cm3(HR 11.7,95%CI 1.47-93.3)和BrainV30>10 cm3(HR 7.08,95%CI 1.52-33.0)与sRN风险显著升高相关。

临床怎么用

  • 5fSRS计划时应关注未受累脑组织V25和V30,尽量使BrainV25<16 cm3且BrainV30<10 cm3以降低sRN风险。
  • 对有既往SRS史的患者应警惕更高的sRN风险并加强随访。

局限性

  • 回顾性研究设计可能引入选择偏倚。
  • 样本量有限(83例患者117个病灶),结论需前瞻性验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: To identify factors predictive of developing symptomatic radiation necrosis (sRN) among patients with either intact or resected brain metastases undergoing five-fraction stereotactic radiosurgery (5fSRS). METHODS: Multi-institutional retrospective review of 117 brain metastases from 83 patients treated with 5fSRS. The cumulative incidence of sRN and predictors of sRN were calculated using Gray's competing risks and Cox regression. RESULTS: The median dose of 5fSRS was 30 Gy (range: 25-40), and 21 lesions (18%) had prior SRS. After a median follow-up of 10.3 months (range: 3-52), the cumulative sRN incidence was 15%, with a median time to sRN of 6.9 months (range: 1.8-31.7). sRN incidence was significantly higher among the lesions treated with prior SRS: hazard ratio (HR): 7.48 [95% confidence interval: 2.57-21.8]. Among lesions without prior SRS, higher volume of uninvolved brain receiving 25 Gy (BrainV25; HR: 1.07 [1.02-1.12]) and 30 Gy (BrainV30; HR: 1.07 [1.01-1.33]) were the most significant factors associated with sRN. Similar results were also observed among the patients with prior SRS. For lesions without prior SRS, BrainV25 > 16 cm3 (HR: 11.7 [1.47-93.3]) and BrainV30 > 10 cm3 (HR: 7.08 [1.52-33.0]) were associated with significantly higher risk of sRN. At two years, the sRN incidence was 21% if violating either dosimetric threshold and 2% if violating neither (p = .007). CONCLUSION: BrainV25 and BrainV30 are significant dosimetric predictors of sRN of brain metastases treated with 5fSRS. In the absence of prior SRS, maintaining BrainV25Gy < 16 cm3 and BrainV30Gy < 10 cm3 may minimize sRN risk.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Andruska N, Kennedy WR, Bonestroo L, et al. Dosimetric predictors of symptomatic radiation necrosis after five-fraction radiosurgery for brain metastases. Radiother Oncol. 2020. PMID: 33310010. doi:10.1016/j.radonc.2020.12.011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。